Advanced Accel (AAAP) Rating
Research professionals at Citigroup have $36.00 TP on Advanced Accel (AAAP). Citigroup’s TP gives a potential upside of 5.51% from the company’s previous stock close. The rating was revealed to investors in a research note on Wednesday morning.
The stock decreased 0.61% or $0.21 on March 16, hitting $34.12. About 87,344 shares traded hands or 58.40% up from the average. Advanced Accelerator Application SA(ADR) (AAAP) has risen 6.00% since February 15, 2016 and is uptrending. It has outperformed by 10.19% the S&P500.
Advanced Accelerator Applications SA is a radiopharmaceutical firm that develops, produces and sells molecular nuclear medicine , diagnostic and therapeutic products. The company has a market cap of $1.34 billion. The Company’s lead therapeutic candidate, Lutathera, is being developed for the treatment of midgut neuroendocrine tumors (NETs). It currently has negative earnings. The Firm has a portfolio of six diagnostic positron emission tomography (PET) and single-photon emission computed tomography (SPECT) products.
According to Zacks Investment Research, “Advanced Accelerator Applications S.A. is a radiopharmaceutical company. The company, develops, produces and commercializes molecular nuclear medicine diagnostic and therapeutic products. Its products in clinical development include Lutathera, Somakit and Annexin V-128. The company’s commercial products include Gluscan /Gluscan 500/Barnascan(R), IASOflu(R), IASOdopa(R), IASOcholine(R), MIBITEC/Adamibi and Leukokit(R). It operates primarily in France, Italy, the United Kingdom, Spain, Portugal, Israel, Switzerland, Germany and Canada. Advanced Accelerator Applications S.A. is headquartered in Saint Genis Pouilly, France.”
Advanced Accel - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.